Welcome to our dedicated page for UroGen Pharma Ltd. SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UroGen Pharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UroGen Pharma Ltd.'s regulatory disclosures and financial reporting.
UroGen Pharma Ltd. reported a Form 144 notice showing the sale of 10,000 shares of common stock. The filing lists the sale date as 05/08/2026 with aggregate proceeds of $300,048.00. The underlying shares were issued on 01/27/2023 following a stock option exercise.
UroGen Pharma’s Chief Medical Officer Mark Schoenberg reported routine equity compensation activity. On June 8, he exercised restricted stock units (RSUs) covering 10,000 ordinary shares, converting them into stock at no exercise price. On the same date, 5,222 ordinary shares were sold at $27.30 per share to satisfy withholding tax obligations tied to this RSU settlement, according to the footnotes. After these transactions, Schoenberg directly held 139,763 ordinary shares of UroGen Pharma.
Mark Schoeberg reported a sale of 10,000 ordinary shares of UroGen Pharma Ltd. The sale is listed with a transaction date of 05/08/2026 and an associated value of 300,048.00. The filing also shows 30,000 ordinary shares issued upon vesting of RSUs on 06/08/2023 (no consideration).
UroGen Pharma reported that it has entered a settlement and license agreement with Teva Pharmaceuticals resolving patent litigation over Jelmyto, its mitomycin-based treatment for upper tract urothelial cancer. Teva had filed an Abbreviated New Drug Application seeking to market a generic Jelmyto before UroGen’s patents expired.
Under the agreement, UroGen will grant Teva a non-exclusive license to sell a generic version of Jelmyto in the United States starting on September 15, 2030, if it receives U.S. Food and Drug Administration approval and subject to certain customary conditions. All related patent cases in the U.S. District Court for the District of Delaware will be terminated, and the agreement will be reviewed by the U.S. Federal Trade Commission and the U.S. Department of Justice.
UroGen Pharma director James A. Robinson Jr. exercised restricted stock units into ordinary shares, increasing his direct share ownership. He acquired 2,000 ordinary shares through an RSU conversion and now directly holds 6,000 ordinary shares, with 2,000 RSUs remaining outstanding as a separate derivative holding.
UroGen Pharma Ltd. reports passive beneficial ownership disclosures by Paradigm BioCapital entities and Senai Asefaw as of 03/31/2026. The filing lists specific share holdings, including 1,703,949 shares reported for Paradigm BioCapital Advisors and related parties and 1,501,473 shares for Paradigm BioCapital International Fund Ltd.
The filing states these holdings represent 3.5% and 3.1% of the class respectively, calculated from 48,708,280 Ordinary Shares outstanding as of 03/31/2026 per the issuer's Form 10-Q. Reporting persons disclaim ownership beyond the shares directly held.
UroGen Pharma Ltd. holdings disclosure: The Toronto-Dominion Bank and TD Securities Inc. report beneficial ownership of 2,618,020 shares of UroGen ordinary shares, representing 5.4% of the class. The filing states TD Bank holds sole voting and dispositive power over 2,616,714 shares and TDSI holds sole voting and dispositive power over 1,306 shares. The statement is a joint Schedule 13G filing and includes a signed joint filing agreement dated May 15, 2026.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 10,000 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of about $30.00 per share, with individual prices ranging from $30.00 to $30.05. After this sale, Schoenberg directly holds 134,985 Ordinary Shares. The transaction was executed pursuant to a pre-arranged trading plan adopted under Rule 10b5-1(c) on 08-15-2025, indicating it was scheduled in advance rather than timed discretionarily.